ALME Stock Overview
Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Almirall, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.78 |
| 52 Week High | €9.96 |
| 52 Week Low | €9.55 |
| Beta | 0.26 |
| 1 Month Change | 0.88% |
| 3 Month Change | n/a |
| 1 Year Change | 2.17% |
| 3 Year Change | -3.17% |
| 5 Year Change | -13.45% |
| Change since IPO | 44.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALME | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.9% | -3.4% | 0.3% |
| 1Y | 2.2% | -14.2% | 0.1% |
Return vs Industry: ALME exceeded the UK Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: ALME exceeded the UK Market which returned 0.1% over the past year.
Price Volatility
| ALME volatility | |
|---|---|
| ALME Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: ALME's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ALME's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 2,026 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology.
Almirall, S.A. Fundamentals Summary
| ALME fundamental statistics | |
|---|---|
| Market cap | €2.31b |
| Earnings (TTM) | €10.15m |
| Revenue (TTM) | €990.63m |
227.2x
P/E Ratio2.3x
P/S RatioIs ALME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALME income statement (TTM) | |
|---|---|
| Revenue | €990.63m |
| Cost of Revenue | €240.43m |
| Gross Profit | €750.20m |
| Other Expenses | €740.05m |
| Earnings | €10.15m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 25, 2025
| Earnings per share (EPS) | 0.048 |
| Gross Margin | 75.73% |
| Net Profit Margin | 1.02% |
| Debt/Equity Ratio | 23.4% |
How did ALME perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield396%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 23:21 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Almirall, S.A. is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elena Fernández | Ahorro Corporación |
| Guilherme Sampaio | Banco BPI, S.A. |
| Álvaro Arístegui Echevarría | Banco de Madrid S.A.U. |